ICON PLC (ICLR) Actualités

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO...

ICON and Its Employees Celebrated for Excellence in the Field of Clinical Research

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

ICON Announces Appointment of Chief Operating Officer

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry...

Form 144 - Report of proposed sale of securities

ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption

Survey spotlights shifting expectations and more measured pace of innovation as use of digital solutions matures within the biotech and pharma...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

ICON plc to Present at the Jefferies London Healthcare Conference

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

ICON Reports Third Quarter 2024 Results

Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]